Enjoying the archive? Get new posts in your inbox.
GLP1
+1
Sep 8, 2026
•
4 min read
Two Free Tools to Make Sense of Obesity Medications
A trial tracker and a medication comparison, free for clinicians and curious patients, plus one methods detail that changes how you read weight loss trials.
Lp(a)
+4
Sep 5, 2026
•
8 min read
The Drug Worked. The Trial Failed.
Pelacarsen lowered Lp(a) in 8,323 patients with established cardiovascular disease. It did not prevent events. What Lp(a)HORIZON teaches about the 1 in 5 — and what it can't.
GLP1
+4
Aug 25, 2026
•
13 min read
Half the Pancreas Is Already Gone. Then We Start Slow.
Type 2 diabetes is endocrine pancreatic failure — and we diagnose it by its last symptom, then treat it with our weakest tools during the only window that reliably reverses it.
CV
+4
Aug 18, 2026
•
14 min read
It's Already on Every Panel. Nobody Reads It.
Remnant cholesterol costs nothing to calculate and predicts events when LDL no longer does. Its first real drug just proved it can prevent pancreatitis, and then failed to move plaque.
